BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tomaz VS, Chaves Filho AJM, Cordeiro RC, Jucá PM, Soares MVR, Barroso PN, Cristino LMF, Jiang W, Teixeira AL, de Lucena DF, Macedo DS. Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression. J Affect Disord 2020;268:188-200. [PMID: 32174477 DOI: 10.1016/j.jad.2020.03.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Li W, Ali T, Zheng C, He K, Liu Z, Shah FA, Li N, Yu ZJ, Li S. Anti-depressive-like behaviors of APN KO mice involve Trkb/BDNF signaling related neuroinflammatory changes. Mol Psychiatry 2021. [PMID: 34642455 DOI: 10.1038/s41380-021-01327-3] [Reference Citation Analysis]
2 Whylings J, Rigney N, de Vries GJ, Petrulis A. Removal of vasopressin cells from the paraventricular nucleus of the hypothalamus enhances lipopolysaccharide-induced sickness behaviour in mice. J Neuroendocrinol 2021;33:e12915. [PMID: 33617060 DOI: 10.1111/jne.12915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Mueller JK, Riederer P, Müller WE. Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence? Pharmacopsychiatry 2022;55:7-15. [DOI: 10.1055/a-1717-2381] [Reference Citation Analysis]
4 Kubick N, Pajares M, Enache I, Manda G, Mickael ME. Repurposing Zileuton as a Depression Drug Using an AI and In Vitro Approach. Molecules 2020;25:E2155. [PMID: 32380663 DOI: 10.3390/molecules25092155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Fourrier C, Baune BT. Null effect of vortioxetine augmentation with celecoxib should not be generalized to other antidepressants - Author's reply. Eur Neuropsychopharmacol 2021;55:110-1. [PMID: 34879305 DOI: 10.1016/j.euroneuro.2021.11.002] [Reference Citation Analysis]
6 Aranda J, Fernández-Arjona MDM, Alén F, Rivera P, Rubio L, Smith-Fernández I, Pavón FJ, Serrano A, Serrano-Castro PJ, Rodríguez de Fonseca F, Suárez J. Sudden cessation of fluoxetine before alcohol drinking reinstatement alters microglial morphology and TLR4/inflammatory neuroadaptation in the rat brain. Brain Struct Funct 2021;226:2243-64. [PMID: 34236532 DOI: 10.1007/s00429-021-02321-9] [Reference Citation Analysis]
7 Strumila R, Lengvenyte A, Olie E, Courtet P, Guillaume S. Null effect of vortioxetine augmentation with celecoxib should not be generalized to other antidepressants. Eur Neuropsychopharmacol 2021;55:84-5. [PMID: 34826785 DOI: 10.1016/j.euroneuro.2021.11.001] [Reference Citation Analysis]
8 Baune BT, Sampson E, Louise J, Hori H, Schubert KO, Clark SR, Mills NT, Fourrier C. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial. Eur Neuropsychopharmacol 2021;53:34-46. [PMID: 34375789 DOI: 10.1016/j.euroneuro.2021.07.092] [Reference Citation Analysis]
9 Chen T, Zheng M, Li Y, Liu S, He L. The role of CCR5 in the protective effect of Esculin on lipopolysaccharide-induced depressive symptom in mice. Journal of Affective Disorders 2020;277:755-64. [DOI: 10.1016/j.jad.2020.08.065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Adamo D, Pecoraro G, Coppola N, Calabria E, Aria M, Mignogna M. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: An open-label randomized trial. Oral Dis 2021;27:1022-41. [PMID: 32790904 DOI: 10.1111/odi.13602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Toshida M, Konishi Y, Ikenouchi A, Okamoto N, Yoshimura R. Colchicine-Resistant Familial Mediterranean Fever With Depressive State Successfully Treated With Escitalopram. Cureus 2021;13:e15145. [PMID: 34164245 DOI: 10.7759/cureus.15145] [Reference Citation Analysis]
12 Yamanashi T, Malicoat JR, Steffen KT, Zarei K, Li R, Purnell BS, Najafi A, Saito K, Singh U, Toth BA, Lee S, Dailey ME, Cui H, Kaneko K, Cho HR, Iwata M, Buchanan GF, Shinozaki G. Bispectral EEG (BSEEG) quantifying neuro-inflammation in mice induced by systemic inflammation: A potential mouse model of delirium. J Psychiatr Res 2021;133:205-11. [PMID: 33360427 DOI: 10.1016/j.jpsychires.2020.12.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
13 Chaves Filho AJM, Mottin M, Soares MV, Jucá PM, Andrade CH, Macedo DS. Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry. Behav Pharmacol 2021;32:123-41. [PMID: 33595954 DOI: 10.1097/FBP.0000000000000585] [Reference Citation Analysis]
14 Oliveira TQ, Chaves Filho AJM, Jucá PM, Soares MVR, Cunha NL, Vieira CFX, Gadelha Filho CVJ, Viana GA, De Oliveira GMF, Macedo DS, Vasconcelos SMM. Lipoic acid prevents mirtazapine-induced weight gain in mice without impairs its antidepressant-like action in a neuroendocrine model of depression. Behav Brain Res 2022;419:113667. [PMID: 34798169 DOI: 10.1016/j.bbr.2021.113667] [Reference Citation Analysis]
15 Park H, Han KM, Jeon H, Lee JS, Lee H, Jeon SG, Park JH, Kim YG, Lin Y, Lee YH, Jeong YH, Hoe HS. The MAO Inhibitor Tranylcypromine Alters LPS- and Aβ-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD. Cells 2020;9:E1982. [PMID: 32872335 DOI: 10.3390/cells9091982] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Yang Y, Li X, Chen S, Xiao M, Liu Z, Li J, Cheng Y. Mechanism and therapeutic strategies of depression after myocardial infarction. Psychopharmacology (Berl) 2021;238:1401-15. [PMID: 33594503 DOI: 10.1007/s00213-021-05784-0] [Reference Citation Analysis]
17 Putnins EE, Goebeler V, Ostadkarampour M. Monoamine Oxidase-B Inhibitor Reduction in Pro-Inflammatory Cytokines Mediated by Inhibition of cAMP-PKA/EPAC Signaling. Front Pharmacol 2021;12:741460. [PMID: 34867348 DOI: 10.3389/fphar.2021.741460] [Reference Citation Analysis]
18 Dionisie V, Filip GA, Manea MC, Manea M, Riga S. The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies. Inflammopharmacology 2021;29:75-90. [PMID: 33164143 DOI: 10.1007/s10787-020-00777-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
19 Ahsan SM, Ahsan SD, Khalid O, Agha H. Usefulness of vortioxetine noted in depression secondary to hypoxic brain injury and residual cognitive deficits. Ther Adv Psychopharmacol 2020;10:2045125320943399. [PMID: 32922733 DOI: 10.1177/2045125320943399] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Gu JY, Xu YW, Feng LP, Dong J, Zhao LQ, Liu C, Wang HY, Zhang XY, Song C, Wang CH. Enriched environment mitigates depressive behavior by changing the inflammatory activation phenotype of microglia in the hippocampus of depression model rats. Brain Res Bull 2021;177:252-62. [PMID: 34653561 DOI: 10.1016/j.brainresbull.2021.10.005] [Reference Citation Analysis]
21 Guo Y, Gan X, Zhou H, Zhou H, Pu S, Long X, Ren C, Feng T, Tang H. Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behaviors via affecting microglial and NLRP3 inflammasome activation. Life Sci 2020;263:118582. [PMID: 33058911 DOI: 10.1016/j.lfs.2020.118582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Alboni S, Benatti C, Colliva C, Radighieri G, Blom JMC, Brunello N, Tascedda F. Vortioxetine Prevents Lipopolysaccharide-Induced Memory Impairment Without Inhibiting the Initial Inflammatory Cascade. Front Pharmacol 2020;11:603979. [PMID: 33613281 DOI: 10.3389/fphar.2020.603979] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Tao W, Hu Y, Chen Z, Dai Y, Hu Y, Qi M. Magnolol attenuates depressive-like behaviors by polarizing microglia towards the M2 phenotype through the regulation of Nrf2/HO-1/NLRP3 signaling pathway. Phytomedicine 2021;91:153692. [PMID: 34411834 DOI: 10.1016/j.phymed.2021.153692] [Reference Citation Analysis]
24 Ostadkarampour M, Putnins EE. Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action. Front Pharmacol 2021;12:676239. [PMID: 33995107 DOI: 10.3389/fphar.2021.676239] [Reference Citation Analysis]
25 Yi S, Zou J, Meng L, Chen H, Hong Z, Liu X, Farooq U, Chen M, Lin Z, Zhou W, Ao L, Hu X, Niu L. Ultrasound Stimulation of Prefrontal Cortex Improves Lipopolysaccharide-Induced Depressive-Like Behaviors in Mice. Front Psychiatry 2022;13:864481. [DOI: 10.3389/fpsyt.2022.864481] [Reference Citation Analysis]
26 De Diego-Adeliño J, Crespo JM, Mora F, Neyra A, Iborra P, Gutiérrez-Rojas L, Salonia SF. Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review. Expert Opin Drug Saf 2021;:1-18. [PMID: 34964415 DOI: 10.1080/14740338.2022.2019705] [Reference Citation Analysis]
27 Kim YR, Park BK, Seo CS, Kim NS, Lee MY. Antidepressant and Anxiolytic-Like Effects of the Stem Bark Extract of Fraxinus rhynchophylla Hance and Its Components in a Mouse Model of Depressive-Like Disorder Induced by Reserpine Administration. Front Behav Neurosci 2021;15:650833. [PMID: 34220460 DOI: 10.3389/fnbeh.2021.650833] [Reference Citation Analysis]
28 Adamo D, Calabria E, Coppola N, Pecoraro G, Mignogna MD. Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update. Ther Adv Psychopharmacol 2021;11:20451253211034320. [PMID: 34497709 DOI: 10.1177/20451253211034320] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]